OSTEOARTHRITIS
Efficacy of various celecoxib doses versus naproxen and placebo in knee osteoarthritis treatment
Mayo Clin Proc. 1999 Nov;74(11):1095-1051003 patients with symptomatic knee osteoarthritis were randomized to be administered either celecoxib 50mg twice daily (b.i.d.), celecoxib 100mg b.i.d., celecoxib 200mg b.i.d., naproxen b.i.d., or placebo. Patients were assessed for efficacy and safety measures over 12 weeks of treatment. Reduction in Western Ontario and McMaster Universities Osteoarthritis Index total scores and OA Severity Index scores after 12 weeks significantly favoured all active treatment groups compared to the placebo group, while pain scores on a visual analog scale were only significantly reduced after 12 weeks compared to placebo in the celecoxib 100mg b.i.d., celecoxib 200mg b.i.d., and the naproxen groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
